Boehringer Ingelheim and IBM Collaborate to Advance Generative AI and Foundation Models for Therapeutic Antibody Development

[ad_1] Ingelheim, Germany and Armonk N.Y., November 28, 2023 – Today, Boehringer Ingelheim and IBM (NYSE:IBM) announced an agreement that will enable Boehringer to use IBM’s foundation model technologies to discover…

Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma

[ad_1] Article content INGELHEIM, Germany & BASEL, Switzerland — Boehringer Ingelheim today announced the acquisition of privately-held T3 Pharmaceuticals AG (“T3 Pharma”), a clinical stage Swiss biotech company, for an…

Pet Medicine Market 2023 COVID19 Impact Analysis and Business Strategy by Key Players: Merck Animal Health,Ceva Sante Animale,Vetoquinol S.A.,Zoetis,Boehringer Ingelheim GmbH,Elanco – theyyscene.ca

[ad_1] “[Latest Version] Pet Medicine Industry”, a new research study published at Adroitmarketresearch.com The 2023 Global Pet Medicine Market study focuses on critical industry information and data, as well as…

Boehringer Ingelheim invests €350m in new biotech R&D facility

[ad_1] The new €350 million biotechnology R&D centre is Boehringer Ingelheim’s largest single investment in Germany to date. Credit: nitpicker / Shutterstock.com Boehringer Ingelheim has inaugurated its new Biologicals Development…